OrbiMed Advisors DXCM Position
Exited6-Fund ConvergenceOrbiMed Advisors exited their position in DexCom Inc. (DXCM) in Q3 2024, after holding the stock for 4 quarters.
The position was first reported in Q4 2023 and has been tracked across 4 quarterly 13F filings.
DXCM is a convergence signal: 6 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Sotagliflozin in 990 days (Dec 31, 2028), making the timing of OrbiMed's position particularly relevant.
About DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Full company profile →Short Interest
5.5%
3.9 days to cover
OrbiMed Advisors DXCM Position History
Frequently Asked Questions
Does OrbiMed Advisors own DXCM?
No. OrbiMed Advisors exited their position in DexCom Inc. (DXCM) in Q3 2024. They previously held the stock for 4 quarters.
How many hedge funds own DXCM?
6 specialist biotech hedge funds currently hold DXCM, including Rock Springs Capital, Redmile Group, Eventide Asset Management and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy DXCM?
OrbiMed Advisors's position in DXCM was first reported in Q4 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's DXCM position increasing or decreasing?
OrbiMed Advisors completely exited their DXCM position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
DXCMCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →